NeurogesX to Present at BioCentury Future Leaders in the Biotech Industry Conference
SAN MATEO, Calif., April 1 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced today that Anthony DiTonno, President and Chief Executive Officer, is scheduled to present at the BioCentury Future Leaders in the Biotech Industry Conference 2010, to be held Thursday, April 8, 2010 at the Millennium Broadway Hotel & Conference Center in New York, New York.
Mr. DiTonno and Stephen Ghiglieri, Executive Vice President, Chief Operating Officer and Chief Financial Officer, will be available to respond to questions during a breakout session immediately following the presentation, and to participate in one-on-one meetings with investors attending the conferences.
Event: BioCentury Future Leaders in the Biotech Industry Conference 2010
Date: Thursday, April 8, 2010
Time: 2:30pm ET (Breakout: 3:00-4:00pm ET)
Place: The Millennium Broadway Hotel & Conference Center, New York, NY (Room 508)
The presentation will be webcast live and can be accessed by visiting the investor relations section of NeurogesX' website at www.neurogesx.com. The webcast will be archived for 90 days.
NASDAQ Opening Bell Ceremony: April 6, 2010
Mr. DiTonno, along with members of the NeurogesX management and sales teams, will ring the ceremonial market opening bell at the NASDAQ Stock Market at 9:30 a.m. ET on Tuesday, April 6, 2010.
A live webcast of the NASDAQ opening bell will be available at: http://www.nasdaq.com/reference/marketsite_events.stm, where it will be archived for one year.
About NeurogesX, Inc.
NeurogesX, Inc. (Nasdaq: NGSX) is a San Francisco Bay Area-based biopharmaceutical company focused on developing and commercializing novel pain management therapies. NeurogesX was founded on the concept that use of prescription strength capsaicin could help manage the pain associated with neuropathic pain conditions. Since its inception, NeurogesX has leveraged its passion to help people with pain to efficiently develop this concept and is now poised to bring its lead product to patients and physicians. In addition, we continue to apply our knowledge and expertise in the development of other novel treatments for pain.
The Company's lead product, QutenzaŽ (capsaicin) 8% patch, is a localized dermal delivery system containing a prescription strength of capsaicin that is currently approved in the United States and the European Union. NeurogesX expects to launch Qutenza in United States in April 2010 for patients with postherpetic neuralgia (PHN). In Europe, Qutenza will be marketed by Astellas Pharma Europe Ltd., (Astellas), the European subsidiary of Tokyo-based Astellas Pharma Inc.
The Company's most advanced product candidate, NGX-1998, is a topically applied, liquid formulation containing a high concentration of capsaicin designed to treat pain associated with neuropathic pain conditions. NGX-1998 has completed three Phase 1 studies.
The Company's early stage product pipeline includes pre-clinical compounds which are prodrugs of acetaminophen and various opioids. The Company has evaluated these compounds in vitro and in vivo.
Safe Harbor Statement
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include but are not limited to: statements about the timing and scope of commercial launch of Qutenza in the United States and European Union and planned commercialization and sales strategies, as well as the expected benefits of such strategies. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to: difficulties or delays in launch or commercialization efforts with respect to Qutenza, including the maintenance of regulatory approvals, unexpected adverse side effects of Qutenza, difficulties or delays in building the sales and marketing infrastructure to support launch or commercialization of Qutenza, decisions by Astellas to halt or delay commercialization efforts, unanticipated additional research and development, commercialization and other costs; potential disputes arising with our strategic partners; potential claims of violating intellectual property of third parties; and the uncertainty of patent protection for NeurogesX intellectual property or trade secrets. For further information regarding these and other risks related to NeurogesX' business, investors should consult NeurogesX' filings with the Securities and Exchange Commission.
NeurogesX, Inc. The Ruth Group Stephen Ghiglieri Sara Pellegrino (investors) Executive Vice President, COO (646) 536-7002 and CFO email@example.com (650) 358-3310 Jason Rando (media) (646) 536-7025 firstname.lastname@example.org
SOURCE NeurogesX, Inc.